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The thromboxane (TX) A2 elicits TP-dependent different platelet responses. Low
amounts activate Src kinases and the Rho–Rho kinase pathway independently of
integrin αIIbβ3 and ADP secretion and synergize with epinephrine to induce aggregation.
Aim of the present study was to investigate the role Src kinases and the interplay
with calcium signals in reactive oxygen species (ROS) generation in the activatory
pathways engaged by TXA2 in human platelets. All the experiments were performed
in vitro or ex vivo. Washed platelets were stimulated with 50–1000 nM U46619 and/or
10 µM epinephrine in the presence of acetylsalicylic acid and the ADP scavenger
apyrase. The effects of the ROS scavenger EUK-134, NADPH oxidase (NOX) inhibitor
apocynin, Src kinase inhibitor PP2 and calcium chelator BAPTA were tested. Intracellular
calcium and ROS generation were measured. Platelet rich plasma from patients treated
with dasatinib was used to confirm the data obtained in vitro. We observed that
50 nM U46619 plus epinephrine increase intracellular calcium similarly to 1000 nM
U46619. ROS generation was blunted by the NOX inhibitor apocynin. BAPTA inhibited
ROS generation in resting and activated platelets. Phosphorylation of Src and MLC
proteins were not significantly affected by antioxidants agents. BAPTA and antioxidants
reduced P-Selectin expression, activation of integrin αIIbβ3and platelet aggregation.
TXA2-induced increase in intracellular calcium is required for Src phosphorylation and
ROS generation. NADPH oxidase is the source of ROS in TX stimulated platelets. The
proposed model helps explain why an incomplete inhibition of TP receptor results in
residual platelet activation, and define new targets for antiplatelet treatment.
Keywords: thromboxane A2, platelets, tyrosine kinase, calcium, NADPH oxidase
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INTRODUCTION
Thromboxane (TX) A2, or its synthetic and natural analogs
have a critical role in platelet activation. These compounds,
depending on the concentration used and their chemical
structure, trigger different signaling pathways downstream the
thromboxane-peroxide (TP) receptor that have been the object
of several investigations. TP-α is the only functional receptor
expressed in platelets and its capability to transduce intracellular
signals depends on G protein coupling. Among Gα proteins
coupled to TP-α, G13 α signals for shape change (Offermanns
et al., 1994; Ohkubo et al., 1996; Klages et al., 1999; Zhang
et al., 2009) whereas Gαq- also leads to platelet secretion
and aggregation (Li et al., 2010a,b). The concentration of TP
agonists is also a major determinant of the platelet response.
Stimulation of washed platelets with the thromboxane TXA2
analog U46619 in the nanomolar range of concentrations,
in the presence of the ADP scavenger apyrase and under
non-aggregating conditions, was shown to induce both Rho
kinase-induced phosphorylation of myosin light chain (MLC)
and tyrosine phosphorylation signals; to note, these pathways
were implicated in triggering of platelet shape change, but not
secretion and aggregation (Minuz et al., 2006). However, platelets
treated with low concentrations of U46619 in the presence of sub-
stimulatory doses of epinephrine, that acts through a Gz coupled
α2 adrenoreceptor, undergo a full release reaction and platelet
aggregation response.
The use of specific inhibitors demonstrated that functional
responses induced by U46619, as well as thrombin, require
Src phosphorylation (Maeda et al., 1993; Gao et al., 2001;
Senis et al., 2015). However, in response to thrombin analogs
Src-family kinases activated via Gα13 were reported to inhibit
Gαq-mediated increase in intracellular calcium and protein
kinase C (PKC) activation, as well as platelet responses (Kim
and Kunapuli, 2011). Additionally, a Src-dependent inhibitory
role of Gα13 on activation of RhoA and platelet responses was
also found in the context of integrin- dependent signaling (Gong
et al., 2010). To add further complexity to the role of Src
kinases in regulation of platelet responses several reports showed
that tyrosine phosphorylation signals, calcium, PI3K and PKC
may synergize in mediating Gαq-dependent platelet responses to
thrombin (Li et al., 2010a,b; Bhavaraju et al., 2011; Xiang et al.,
2012).
Crosstalk of Src with other pathways of platelet activation
triggered by TXA2 analogs has not been extensively investigated.
Calcium mobilization was implicated in the functional responses
to platelet agonists and is indispensable for TP-dependent platelet
aggregation (Berna-Erro et al., 2012). However, free intracellular
calcium increase is very limited in response to low concentrations
of U46619 or the partial TXA2 mimetic 8-iso-Prostaglandin
(PG) F2α (Minuz et al., 1998, 2002; Zhang et al., 2009). Moreover,
it has been clearly demonstrated that some functional platelet
responses occur via calcium-independent pathways (Paul et al.,
1999; Huang et al., 2007). Reactive oxygen species (ROS)
generation may certainly play a role as indicated by the evidence
that platelet activation is blunted by antioxidants and NADPH
oxidase inhibitors (Begonja et al., 2005; Tang et al., 2011;
Violi and Pignatelli, 2014). Notably, ROS may be implicated
in Src- and calcium-mediated signaling downstream G
protein-coupled receptors. In fact, hydrogen peroxide was
shown to induce Src activation (Inazu et al., 1990) and to be
implicated in the activation of store-mediated calcium entry
(SMCE) in human platelets (Rosado et al., 2004).
The present study aimed at defining the signaling pathway
implicated in platelet activation induced by TXA2 analogs,
further analyzing the role of Src kinases and the interplay of
calcium and ROS in platelet activation to define the mechanisms
responsible for their selectivity in eliciting different platelet
functional responses.
MATERIALS AND METHODS
Ethics Statement
The study protocol was approved by the Ethics Committee for
Clinical Research of the Provinces of Verona and Rovigo. All
subjects gave written informed consent in accordance with the
Declaration of Helsinki.
Reagents
2-mercaptoethanol, Acetyl Salicylic Acid (ASA), apyrase VII,
bromophenol blue, bovine serum albumin (BSA), citric acid,
dextrose, cytochalasin B, EGTA, Hepes, KCl, NaCl, Na2HPO4,
sodium citrate, SDS 20% and Tween-20 were supplied by
Sigma Aldrich (Milan, Italy). Apocynin, epinephrine bitartrate
(epinephrine, epi), Gö 6976, U46619, PP2 and Y27632 were
supplied by Calbiochem (San Diego, CA, United States).
Eptifibatide (Integrilin) was supplied by GlaxoSmithKline
(Greenford, Middlesex, United Kingdom). EUK-134 and
8-iso-PGF2α, were obtained from Cayman Chemical (Ann
Arbor, MI, United States). ECL R© reagent, HRP (horseradish
peroxidase)-conjugated donkey anti-(rabbit Ig), goat antimouse
IgG-HRP and Hybond C nitrocellulose were obtained by GE
Healthcare Europe GmbH (Milan, Italy). Anti-phospho-Tyr
(clone 4G10) were purchased from Millipore (Billerica, MA,
United States). Anti phospho-Src family (Tyr416) and anti-Src
(clone GD11) were purchased from Cell Signaling (Danvers,
MA, United States). Anti phospho-Tyr PY99, anti-phospho MLC
(myosin light chain; Thr18/Ser19) and anti MLC were purchased
from Santa Cruz Biotechnology (Dallas, TX, United States).
ADP and Collagen were supplied by Mascia Brunelli (Milan,
Italy). Fura 2-AM and BAPTA/AM was obtained by Molecular
Probes (Thermo Fisher Scientific, Waltham, MA, United States).
PE-labeled CD62P-Selectin (clone CLBThromb/6) and IgG1
(Mouse) isotype were purchase from Beckman Coulter (Milan,
Italy). FITC-labeled monoclonal antibody PAC-1 and FITC
Mouse IgM, κ isotype control were from BD Biosciences (Milan,
Italy). Dasatinib was purchased from Selleckchem (Munich,
Germany).
Preparation of PRP for the ex vivo Analysis of Platelet
Function
Platelet-rich plasma (PRP) was prepared from blood of patients
treated with dasatinib and from blood of healthy volunteer,
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matched for age and sex, not taking any drugs in the previous
3 weeks.
Blood was taken 3 and 24 h after drug administration,
corresponding to the expected peak of dasatinib in peripheral
blood. Concerning the patients characteristics, the mean
time from diagnosis of chronic myeloid leukemia (CML) in
chronic phase was 25,5 months (range 6–60). All the patients
discontinued treatment with imatinib due to adverse reaction
or treatment failure and were on treatment with dasatinib
(100 mg/day in four patients, 140 mg/day in one patient) from
9 months (range 2–32). In all subjects blood was drawn by
venepuncture into 3,6 ml vacutainer (Venosafe, Terumo) with
trisodium citrate 0.109 M. To block platelets cyclooxygenase
activity ASA 100 µM was added to blood samples. For
western blot experiments blood was collected in 3 ml Hirudine
Blood Tube (Verum Diagnostica) in the presence of trisodium
citrate 3.8%.
Platelet-rich plasma was obtained by centrifugation
of blood at 200 × g at room temperature for 10 min
and platelet count was estimated by an automated cell
counter.
Preparation of Washed Platelets for the in vitro
Experiments
For the in vitro experiments washed platelets were used. We
used as anticoagulant an acid/citrate/dextrose mixture (sodium
citrate14 mM citric acid, 11.8 mM and dextrose 18 mM) added
with ASA 100 µM and apyrase VII 0.4 U mL−1. Washed
platelets were obtained by centrifugation of blood samples at
200 × g for 10 min to obtain a PRP. This was followed
by further centrifugation at 700 × g for 15 min at room
temperature; platelets were then suspended in Hepes buffer
(Hepes 10 mM, pH 7.4, NaCl 145 mM, KCl 5 mM, Na2HPO4
0.5 mM and glucose 6 mM) in the presence of ASA 100 µM and
apyrase VII 10 U mL−1. Platelet suspensions were kept at room
temperature and tested within 2 h. When indicated, platelets were
incubated (15 min at 37◦C) with inhibitors/antioxidants before
stimulation.
Immunoblot Analysis
Washed platelets (150 × 106 platelets) were pre-incubated at
37◦C, under static conditions, in the presence or absence of
antioxidants/inhibitors as indicated in the Section “Results.”
Then the platelets were stimulated for 40 s with specific agonists
and in the presence of Ca2+ 1 mM. After stimulation 4X
sample buffer (Tris/HCl 100 mM pH 6.8, 2-mercaptoethanol
200 mM, SDS 4%, glycerol 20% and Bromophenol Blue 0.4%)
was added to the samples, which were then boiled for 3 min
and stored at −80◦C until use. Samples were separated by
SDS/PAGE as previously described (Minuz et al., 2006). For
western blot analysis in the ex vivo experiments PRP was
stimulated for 40 s at 37◦C with agonists in the presence of
apyrase VII 10 U mL−1 and eptifibatide 10 µg mL−1. The
reaction was stopped with the addition of Hepes buffer (2 ml)
and after centrifugation at 10000 × g for 10 s, platelets were
lysed in 4X sample buffer at 95◦C and treated as described
before.
Platelet Free Intracellular Calcium [Ca2+]i
[Ca2 + ]i was measured in washed platelets with the fluorescence
indicator Fura 2-AM, according to the method described by
Pollock et al. (1986).
Washed platelets suspended in HEPES buffer (4 × 108
cells mL−1), in the presence of apyrase VII 10 U mL−1 and
eptifibatide 10 µg mL−1, were loaded with Fura 2-AM 2 µM
for 25 min at 32◦C. After centrifugation at 200 × g for 10 min
40× 106 platelets were placed in quartz cuvettes and fluorescence
measurements were carried out at 37◦C using a QuantaMaster
spectrofluorometer (PTI, Japan) with magnetic stirring. After
platelets stimulation the fluorescence signal was monitored by
using double excitation wavelength of 340 and 380 nm and
an emission wavelength of 510 nm. [Ca2+]i was expressed as
concentration using a Kd for Fura-2 of 226 nM; the calculations
were done according to the equations of Grynkiewicz et al.
(1985).
Platelet Aggregation
For in vitro aggregation washed platelets (300.000 cells µL−1)
were pre treated with antioxidants/inhibitors at 37◦C for 10 min
in the presence of apyrase VII 10 U mL−1 and ASA 100 µM.
Platelets were transferred into cuvettes and incubated with CaCl2
1 mM and MgSO4 1 mM for 1 min at 37◦C under continuous
stirring at 1000 rpm. Platelet aggregation was monitored for
5 min after the addition of the agonist, using the Born’s
turbidimetric method in a four channel aggregometer (APACT
4004, Labitech and Chrono-log Model 700 Whole Blood/Optical
Lumi-Aggregometer, Chrono-Log Corp.). The rate of platelet
aggregation was calculated as change in percentage of transmitted
light (%T), according to Born and Cross (1963). For the ex vivo
experiments, aggregation tests were performed using PRP in the
presence/absence of apyrase VII 10 U mL−1 with platelet count
adjusted at 300.000 platelets µL−1.
Flow-Cytometry Analysis of Platelet a Granule
Secretion and αIIbβ3 Activation
For the in vitro and ex vivo experiments, washed platelet
suspension (50.000 platelets µL−1) was incubated at 37◦C for
15–20 min with or without antioxidants/inhibitors as indicated
in the Section “Results.” PE-labeled anti-CD62 (P-Selectin) and
FITC-labeled monoclonal antibody PAC-1, a ligand mimetic
monoclonal antibody that specifically binds to the active
form of integrin αIIbβ3 complex, were added to platelet
suspensions before the agonists at room temperature. In all
the experiments two isotype-matched irrelevant mouse IgG1
FITC and PE labeled were included as negative control.
After incubation at room temperature, samples were diluted
in PBS and analyzed by flow cytometry (Cytomics FC 500;
Beckman Coulter), using dual color fluorescence. Platelets were
identified on the basis of their Forward Scatter and Side Scatter
properties.
For the in vitro and ex vivo experiments, the expression of
P-selectin and the activation of the fibrinogen receptor with
PAC-1 were studied in PRP diluted at 20.000 platelets µL−1 in
presence of ASA 100 µM and in the presence or absence of
apyrase VII 10 U mL−1.
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Measurement of ROS
Reactive oxygen species generation was measured using a
commercial kit according to the manufacturer’s instruction
(Total ROS/Superoxide Detection Kit, Enzo Life Sciences).
Briefly, washed platelets (100.000 µL−1) were pre-treated, at
37◦C for 15 min, in the absence or presence of apyrase VII 10 Um
L−1 with apocynin 300 µM and BAPTA/AM 20 µM according
to the experimental procedures. Platelets were collected by
centrifugation at 400 × g for 5 min, incubated with 1 µM
ROS/Superoxide detection mix for 60 min at 37◦C in the
presence or absence of the agonist. Changes in the fluorescence
intensity were measured using a microplate fluorescence reader
(Victor X, PerkinElmer) at excitation/emission wavelengths of
488/520 nm.
In each of the previously described experimental sets all
the tested conditions were analyzed using platelet preparations
obtained from a single blood samples, replicates were always from
different blood donors.
Statistics
For statistical analysis, all data were analyzed with GraphPad
Prism software v.5.03 (GraphPad Software, San Diego, CA,
United States). Data are presented as Mean and Standard Error
in figures or Mean and Standard deviation in tables. Data
concerning all the parameters included in each experimental set
were obtained from the analysis of a single platelet preparation
(n subjects). This allowed to perform the statistical analysis
for multiple comparisons using the One-way ANOVA with
post hoc pairwise comparisons performed using Newman–Keuls
or Dunnett’s test, as indicated in individual tables and figure
legends, or the Two-way ANOVA followed by Bonferroni’s test,
as indicated in figure legends. P-value < 0.05 was assumed as
statistically significant.
RESULTS
Functional Role of Tyrosine Kinases on
Platelet Responses to Soluble Agonists:
In vitro and ex vivo Study
Based on our previous studies implicating tyrosine
phosphorylation signals in platelet responses to a combination
of low doses of a thromboxane analog and sub-stimulatory doses
of epinephrine (Minuz et al., 2006), we addressed whether a
Src-family kinase inhibitor affected platelet function in vitro
and ex vivo. Using washed platelets in the presence of the
ADP scavenger apyrase and ASA we found that the specific
inhibitor PP2 inhibited both α granule secretion (CD62P
expression %) and the expression of the active form of the
fibrinogen receptor (PAC-1 binding %) in response to low doses
of U46619 plus epinephrine (Table 1). In contrast, the response
to optimal, stimulatory doses of U46619 was only marginally
affected.
The role of a tyrosine phosphorylation pathways in this
response was further investigated examining platelets obtained
from patients affected by CML treated with dasatinib, an
TABLE 1 | Effects of the Src-family inhibitor PP2 on the expression of P-Selectin
(CD62) and the active form of the fibrinogen receptor, as assessed using the
monoclonal antibody PAC-1.
Conditions Active fibrinogen
receptor
CD62P
Resting (n = 3) 0.7 ± 0.6 1.6 ± 1.3
+ U46619 1 µM 7.8 ± 5.4 14.0 ± 4.5∗
+ U46619 1 µM + PP2 10 µM 5.2 ± 6.1 12.3 ± 7.5
Resting (n = 5) 1.6 ± 1.9 1.9 ± 1.1
+ U46619
50 nM + Epinephrine 10 µM
26.3 ± 13.1∗† 26.6 ± 9.2∗†
+ U46619
50 nM + Epinephrine 10 µM +
PP2 10 µM
11.3 ± 5.8∗† 8.6 ± 3.1∗†
Washed platelets were stimulated by U46619 1 µM and U46619 50 nM with
epinephrine 10 µM in the presence of ASA 100 µM and apyrase VII 10 U mL−1.
Data are expressed as % of positive events. Repeated-measures One-way ANOVA,
followed by Newman–Keuls as post hoc test was applied to compare each agonist
and inhibitors with resting conditions. Mean ± SD, ∗P < 0.05 vs. resting platelets,
†P < 0.05 stimulated –PP2 vs. stimulated +PP2.
Abl/Src dual specificity inhibitor. We found that in platelets
collected 3 h after the oral administration of dasatinib,
the constitutive phosphorylation of Src was markedly lower
than in platelets collected 24 h after drug administration
(Figure 1). Examining platelet responses in PRP we detected
a robust increase in P selectin expression (CD 62) and
αIIbβ3 activation when U46619 1 µM or U46619 50 nM in
combination with epinephrine 10 µM were used (Table 2).
Notably, these responses were significantly lower in platelets
from CML patients after 3 h from administering dasatinib
and went back to pre-treatment levels after 24 h. Reductions
in constitutive Src phosphorylation, P-selectin expression and
αIIbβ3 activation after 3 h from dasatinib treatment correlated
with a decreased aggregation response in response to U46619
1 µM or U46619 50 nM in combination with epinephrine 10 µM
(Table 3). The effects of collagen and ADP are shown for
comparison.
Calcium Mobilization in Response to
Thromboxane A2 Analogs
Considering that calcium signals play an indispensable role
in platelet activation (Varga-Szabo et al., 2009) we addressed
whether the different doses of the TXA2 analog U46619,
tested alone or with epinephrine, which we found to elicit a
tyrosine phosphorylation response, were also able to trigger
calcium mobilization (Figure 2). Experiments were performed
in the presence of ASA, apyrase, and eptifibatide using washed
platelets under stirring. Compared to doses of 1 µM, U46619
50 nM triggered only a modest increase of calcium transients
(peak value increment of about 260 nM for 1 µM U46619
and 60 nM for U46619 50 nM). However, when added in
combination with epinephrine 10 µM, that per se was unable
to trigger any increase in cytosolic calcium, U46619 50 nM
triggered a net calcium response (peak value increment about
140 nM) that was more prolonged than that induced by
U46619 1 µM. The increase in free intracellular calcium
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FIGURE 1 | Ex vivo effect of dasatinib on Src phosphorylation. PRP was isolated in the presence of ASA 100 µM and apyrase VII 10 U mL−1 from health volunteer
(n = 7) or from patient (n = 5) 3 and 24 h post treatment with dasatinib. PRP was stimulated by U466191 µM, U46619 50 nM, epinephrine (epi) 10 µM, U46619
50 nM plus epinephrine 10 µM. Two-way ANOVA followed by Bonferroni’s test was applied to compare platelet response to each agonist with resting conditions in
the presence or absence of dasatinib. Data are expressed as Mean ± SE, ∗P < 0.05, ∗∗P < 0.01.
induced by low doses U46619 alone or in combination with
epinephrine required calcium influx, since it was almost
abolished in the presence of EGTA, while calcium increase
induced by U46619 1 µM was attenuated, but not abolished
by EGTA (Figure 3). To further explore the selectivity of
calcium signals downstream the TP receptor, we tested the
effects of 8-iso-PGF2α 10 µM under the same experimental
conditions. However, either alone or in combination with
epinephrine, 8-iso-PGF2α failed to elicit any calcium response
(Figure 2).
Calcium mobilization was not altered by any of the tested
antagonists of specific pathways: the Src kinase inhibitor PP2,
ROS scavenger NADPH oxidase inhibitor apocynin, Rho kinase
inhibitor Y27632, the protein kinase C inhibitor Gö 6976
(Table 4).
Cross-Talk Between Calcium and
Tyrosine Phosphorylation Signals in
Platelet Activation
In order to understand whether tyrosine phosphorylation
triggered by low U46619 doses (Minuz et al., 2006) was distinct or
downstream calcium signals, we examined total protein tyrosine
phosphorylation in control platelets or platelets loaded with the
calcium-chelator BAPTA. As reported in Figure 4A, U46619
50 nM was as potent as 1 µM in increasing phosphorylation of
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TABLE 2 | Ex vivo effect of dasatinib on the expression of P-Selectin (CD62%) and the active form of fibrinogen receptor (%).
CD62 Active fibrinogen receptor
Conditions Control n = 7 3 h post
Dasatinib
n = 5
24 h post
Dasatinib
n = 5
Control
n = 7
3 h post
Dasatinib
n = 5
24 h post
Dasatinib
n = 5
Apyrase 10 U mL−1
Resting 1.2 ± 1.1 0.4 ± 0.3 1.4 ± 1.0 0.4 ± 0.1 0.3 ± 0.1∗ 0.2 ± 0.1∗
U46619 1 µM 9.0 ± 3.3 5.5 ± 6.7 17.3 ± 12.5 5.8 ± 3.4 2.0 ± 2.4∗ 10.3 ± 9.4
U46619 50 nM 1.9 ± 1.6 0.4 ± 0.4 4.5 ± 4.7∗ 0.6 ± 0.2 0.2 ± 0.1∗ 1.1 ± 1.7
Epinephrine 10 µM 6.7 ± 3.9 1.3 ± 1.7∗† 8.4 ± 4.3∗ 3.3 ± 2.4 0.4 ± 0.4∗ 3.9 ± 3.1∗
U46619 50 nM + epinephrine 10 µM 24.5 ± 16.6 7.4 ± 9.4 24.5 ± 23.1 14.3 ± 11.1 1.8 ± 2.3∗ 15.8 ± 16.0
U46619 1 µM + eptifibatide 10 µg mL−1 22.7 ± 10.9 11.6 ± 11.8 28.0 ± 17.4 0.4 ± 0.2 0.6 ± 0.8 0.2 ± 0.1∗
ADP 5 µM 2.2 ± 1.6 0.9 ± 0.9† 2.7 ± 1.3 0.5 ± 0.1 0.2 ± 0.1† 0.5 ± 0.4
Collagen 10 µg mL−1 2.4 ± 0.9 1.6 ± 1.3 2.9 ± 0.8 1.5 ± 0.5 1.3 ± 0.6 1.5 ± 0.6
Collagen 10 µg mL−1 + U46619 50 nM 3.9 ± 0.9 2.5 ± 1.6 4.7 ± 2.8 6.0 ± 9.6 1.5 ± 0.6 3.0 ± 1.7
Without apyrase
Resting 1.7 ± 1.4 0.2 ± 0.1∗ 1.7 ± 1.4 0.4 ± 0.2 0.2 ± 0.1 0.2 ± 0.1
U46619 1 µM 31.5 ± 19.2 11.0 ± 12.4† 39.2 ± 31.4 29.7 ± 24.7 3.9 ± 5.0∗† 33.6 ± 27.7
U46619 50 nM 2.5 ± 1.5 0.4 ± 0.2∗† 6.36 ± 7.7∗ 0.8 ± 0.5 0.2 ± 0.1∗ 2.6 ± 3.9
Epinephrine 10 µM 8.2 ± 3.6 1.2 ± 1.4∗† 10.5 ± 5.8 6.6 ± 3.9 0.6 ± 0.6∗† 7.9 ± 5.9
U46619 50 nM + epinephrine 10 µM 32.2 ± 20.8 9.2 ± 11.4† 32.0 ± 25.6 24.4 ± 15.7 2.5 ± 3.1∗† 27.3 ± 25.3
U46619 1 µM + eptifibatide 10 µg mL−1 64.2 ± 16.7 24.4 ± 26.5∗† 47.6 ± 34.9∗ 0.2 ± 0.1 0.2 ± 0.1 0.1 ± 0.1
ADP 5 µM 40.5 ± 8.1 21.1 ± 20.9† 41.4 ± 18.1 49.7 ± 16.7 20.5 ± 19.4∗† 46.7 ± 25.5
Collagen 10 µg mL−1 2.6 ± 0.9 1.5 ± 0.9† 3.4 ± 1.0 1.6 ± 0.6 1.3 ± 0.5 1.8 ± 0.7
Collagen 10 µg mL−1 + U46619 50 nM 4.1 ± 0.6 2.3 ± 1.2∗† 4.6 ± 2.9 2.7 ± 1.1 1.5 ± 0.4† 3.6 ± 1.6
Mean ± SD, ∗P < 0.05: vs. control, †P < 0.05 3 h post dasatinib vs. 24 h post dasatinib. PRP was prepared in the presence of ASA 100 µM with and without apyrase
VII 10 U mL–1 from healthy volunteers or patients, 3 and 24 h post treatment with dasatinib, in the presence or absence of eptifibatide 10 µg mL–1. Data are expressed
as % of positive events. One-way ANOVA, followed by Newman–Keuls as post hoc test was applied to compare each agonist in the presence or absence of dasatinib
with resting conditions in patients and controls. Active fibrinogen receptor and CD62 were separately analyzed.
TABLE 3 | Effect of dasatinib on platelet aggregation (% aggregation at 5 min).
Conditions Control 3 h post Dasatinib 24 h post Dasatinib
Apyrase 10 U mL−1
U46619 1 µM 57.9 ± 7.7 21.4 ± 20.7∗† 51.4 ± 27.7
Epinephrine 10 µM 27.4 ± 6.4 7.9 ± 8.8∗† 30.8 ± 11.2
U46619 50 nM + Epinephrine 10 µM 30.9 ± 10.0 18.6 ± 25.6 31.7 ± 10.1
Collagen 10 µg mL−1 17.4 ± 7.1 6.1 ± 1.6∗† 18.9 ± 8.9
ADP 5 µM 0.0 ± 0.0 1.3 ± 2.2 0.2 ± 0.5
Collagen 10 µg mL−1 + U46619 50 nM 19.8 ± 9.2 3.5 ± 2.5∗ 19.8 ± 15.6
Without apyrase
U46619 1 µM 81.2 ± 9.0 15.9 ± 28.6∗ 62.5 ± 32.3
Epinephrine 10 µM 25.5 ± 5.5 7.9 ± 5.6∗† 26.2 ± 8.5
U46619 50 nM + Epinephrine 10 µM 35.5 ± 18.6 17.9 ± 23.7 32.2 ± 12.7
Collagen 10 µg mL−1 74.9 ± 11.8 10.5 ± 15.1∗† 66.4 ± 12.2
ADP 5 µM 76.2 ± 6.3 31.6 ± 30.6∗ 69,1 ± 9.1
Collagen 10 µg mL−1 + U46619 50 nM 74.8 ± 16.9 9.8 ± 13.9∗† 63.7 ± 13.5
Mean ± SD, n = 5, ∗P < 0.05 vs. control, †P < 0.05 3 h post dasatinib vs. 24 h post dasatinib. PRP of patients/health volunteer was stimulated in the presence or
absence of apyrase VII 10 U mL−1 and ASA 100 µM, respectively, 3 and 24 h post dasatinib administration. One-way ANOVA, followed by Newman–Keuls as post hoc
test was applied to compare each agonist with or without inhibitor and controls.
tyrosine residues. However, loading of platelets with BAPTA that
blunted increase in intracellular calcium (not shown), decreased
U46619-stimulated tyrosine phosphorylation to background
levels. Similar results were obtained examining Src tyrosine
phosphorylation in response to U46619 50 nM in combination
with epinephrine 10 µM in time-course experiments (Figure 4B)
and U46619 1 µM or U46619 50 nM alone and in combination
with epinephrine 10 µM (Figure 4C). We conclude that
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FIGURE 2 | Maximal release of intracellular calcium in washed and non-aggregating platelets (in presence of ASA 100 µM, apyrase VII 10 U mL−1, eptifibatide 10 µg
mL−1) stimulated by U46619 1 µM, U46619 50 nM, U46619 50 nM + epinephrine (epi) 10 µM, epi alone 10 µM, 8-iso PGF2α 10 µM, 8-iso PGF2α 10 µM + epi
10 µM (Ca2+ nM). Repeated-measures Two-Way ANOVA was applied to compare the effects of platelets agonists at different time points. Significant differences
(P < 0.0001) were observed comparing U46619 1 mmol/L with all the other agonists, except U46619 50 nM + epi 10 µM. Data are expressed as Mean ± SE.
increase in intracellular calcium precedes and regulates tyrosine
phosphorylation signals in platelets stimulated with U46619
alone or in combination with epinephrine.
Role of Changes in Free Intracellular
Calcium in Functional Platelet
Responses
In order to understand whether an increase in intracellular free
calcium plays a critical role also in triggering platelet responses,
we addressed the expression of the active form of the fibrinogen
receptor, secretion of α granules, platelet shape change and
aggregation in platelets loaded with BAPTA and stimulated
with U46619 alone or in combination with epinephrine. As
shown in Table 5, loading of platelets with BAPTA decreased
both expression of an activation epitope in αIIbβ3 and the
degranulation response in response to a combination of low
U46619 doses and epinephrine to background levels. Blunting
the calcium increase also resulted in inhibition of the response
to optimal (1 µM) doses of U46619. Similar results were
obtained examining platelet aggregation (Figure 5). We conclude
that calcium signals play an essential role in regulating
both tyrosine phosphorylation and functional responses in
platelets.
ROS Generation in Platelets Stimulated
With U44619
Considering that TP stimulation with U46619 was reported to
induce ROS generation in a dose-dependent manner (Begonja
et al., 2005; Wilson et al., 2009), we addressed whether ROS
are implicated in the platelet response to low U46619 doses in
combination with epinephrine using two different inhibitors of
ROS generation (Dharmarajah et al., 2010). We found that both
apocynin and EUK-134 strongly inhibited platelet aggregation
induced by both optimal dose of U46619 and a combination
of low U46619 doses and epinephrine (Figure 5). Additionally,
these compounds inhibited both the expression of an activation
epitope in αIIbβ3 and the degranulation response (Table 6).
In order to know whether in our assay conditions platelets
were able to generate ROS we assayed ROS generation in response
to U46619 either alone or in combination with epinephrine. As
reported in Figure 6A, U46619 50 nM triggered a limited increase
of ROS generation. While epinephrine alone did not trigger any
significant increase in ROS generation, this was observed when
epinephrine was used in combination with U46619 50 nM or
when U46619 1 µM was used as a stimulus (P < 0.001 and
P < 0.01, respectively, applying One way ANOVA followed by
Dunnett’s test to analyze cumulatively data from the two sets of
experiments shown in Figures 6A,B). Notably, ROS generation
was blunted in platelets loaded with the calcium chelator BAPTA,
thus suggesting that calcium signals are located upstream the
activation NADPH oxidase. To investigate the relations between
Src phosphorylation and ROS generation, we analyzed the effects
of the specific dual Abl/Src inhibitor dasatinib, added in vitro
to washed platelets that subsequently stimulated with agonists
(PP2 could not be used, since interfering with fluorescence
emission). In the presence of dasatinib, limited reduction in
ROS generation was observed under basal conditions and after
stimulation with 1 µM U46619, but not when 50 nM U46619
was tested alone or in combination with 10 µM epinephrine
(Figure 6B). By comparison, collagen 10 µg mL−1, which
was the strongest stimulus for platelet ROS generation in our
experimental condition (Figures 6A,B), when tested in washed
platelets pretreated with dasatinib reduced ROS generation by
approximately 40% (Figure 6B). Cumulating the data from the
two sets of experiments (n = 12), we observed that only 1 µM
U46619 and 50 nM U46619 plus 10 µM epinephrine induced
significant increase in ROS generation (P < 0.001 and P < 0.01,
respectively, by One way ANOVA followed by Donnett’s post hoc
test).
Frontiers in Pharmacology | www.frontiersin.org 7 September 2018 | Volume 9 | Article 1081
fphar-09-01081 September 26, 2018 Time: 15:10 # 8
Minuz et al. Thromboxane A2 and Calcium Signaling in Platelets
FIGURE 3 | Intracellular Ca2+ release in stimulated washed platelets in presence/absence of extracellular calcium. Washed platelets in non-aggregating condition
(eptifibatide 10 µg mL−1, ASA 100 µM, apyrase VII 10 U mL−1) were stimulated by U46619 1 µM, U46619 50 nM, U46619 50nM + epinephrine 10 µM, and
epinephrine 10 µM. Fluorescent emission at 510 nm was measured induced by double excitation wavelength of 340 and 380 nm. The ratio of the two fluorescence
is proportional to the concentration of the released intracellular calcium. Repeated-measures Two-Way ANOVA was applied to compare the effects of platelets
agonists at different time points. Significant differences (P < 0.0001) were observed comparing intracellular Ca2+ release induced by U46619, but not epinephrine
(P = n.s.), with and without EGTA. Data are expressed as Mean ± SE.
TABLE 4 | Maximal release of intracellular calcium (expressed in nM) in washed platelets (in the presence of ASA 100 µM, apyrase 10 U mL−1, eptifibatide 10 µg mL−1)
stimulated by U46619 1 µM, U46619 50 nM, U46619 50 nM + epinephrine 10 µM, epinephrine 10 µM, 8-iso-PGF2α 10 µM, 8-iso- PGF2α 10 µM + epinephrine
10 µM.
Conditions Resting U46619 1 µM U46619 50 nM U46619 50 nM + Epi 10 µM Epi 10 µM
Platelets (n = 15) 43.4 ± 22.8 298.9 ± 91.8∗ 104.8 ± 43.3∗ 185.4 ± 69.5∗† 53.7 ± 35.1
+ Apocynin 300 µM (n = 6) 49.6 ± 11.9 276.3 ± 70.9∗ 119.2 ± 46.3∗ 175.1 ± 59.9∗ 77.1 ± 4.6
+ EUK-134 250 µM (n = 6) 58.4 ± 8.9 233.7 ± 43.8∗ 115.6 ± 15.1∗ 181.1 ± 46.6∗† 78.8 ± 26.3
+ PP2 10 µM (n = 3) 63.6 ± 7.9 317.1 ± 80.1∗ 148.5 ± 49.0∗ 203.9 ± 47.2∗ 88.7 ± 15.3
+ Y27632 30 µM (n = 3) 65.0 ± 16.1 293.9 ± 23.7∗ 134.8 ± 43.2∗ 179.0 ± 54.4∗ 139.3 ± 2.4∗
+ Cytochalasin B 20 µM (n = 3) 18.0 ± 4.27 226.1 ± 9.2∗ 69.4 ± 15.6 − 52.4 ± 9.7
+ Gö 6976 (n = 3) 48.8 ± 25.3 301.8 ± 85.4∗ 51.0 ± 38.5 239.8 ± 22.6∗† 46.2 ± 36.5
Resting 8-isoPGF2α 10 µM 8-isoPGF2α 10 µM + Epi 10 µM
Platelets (n = 3) 30.5 ± 4.4 62.0 ± 9.9∗ 74.6 ± 13.4∗
Mean ± SD, ∗P < 0.05 resting vs. activated. †P < 0.05 U46619 50 nM + epinephrine 10 µM vs. U46619 50 nM and epinephrine 10 µM. One-way ANOVA, followed by
Newman–Keuls as post hoc test was applied to compare each agonist in the presence or absence of inhibitors with resting conditions.
DISCUSSION
The major new finding from the present study is the
requirement of calcium signals both for Src tyrosine kinase
activation and NOX dependent ROS-generation downstream
TP receptor. These three signals induce platelet secretion and
aggregation when platelets are stimulated by low concentrations
of U46619 and epinephrine. Quantitatively different increases
in free intracellular calcium concentrations differentiate platelet
responses to U46619.
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FIGURE 4 | Western Blotting analysis of tyrosine (A) and Src (B,C) phosphorylation. Washed platelets were isolated in non-aggregating condition (eptifibatide 10 µg
mL−1, ASA 100 µM, apyrase VII 10 U mL−1) and stimulated with agonists. The reaction was stopped by adding sample buffer 4× at 100◦C. (B) Typical pattern of
Src phosphorylation after stimulation of 10, 20, 40, and 60 s with U46619 50 nM + epi 10 µM in condition of intracellular calcium-presence or absence. Graphic is
representative of four experiment. (C) Typical pattern of Src phosphorylation after stimulation of 40 s with U46619 1 µM, U46619 50 nM, U46619 50 nM + epi
10 µM, and epi 10 µM in presence or absence of BAPTA 20 µM. Graphic shows five experiments. Repeated-measures Two-Way ANOVA was applied to compare
the effects of platelets agonists on Src phosphorylation at different time points in the presence of different agonists (B,C). Mean ± SE, ∗P < 0.05, ∗∗P < 0.01,
∗∗∗P < 0.001.
Stimulation of washed platelets with low concentration
(50 nM) of U46619 was previously shown to elicit MLC
phosphorylation through a signaling pathway that requires Src
and Rho-Rho kinase to induce platelet shape change (Li et al.,
2010a). In the presence of epinephrine 10 µM plus U46619
50 nM, both release reaction and platelet aggregation were
induced (Minuz et al., 2006). As confirmed by the present
investigation, these events occur independently of released ADP.
In fact, both the activation of the fibrinogen receptor and platelet
aggregation, but not platelet secretion, induced by 1 µM U46619
are blunted in the presence of 10 U mL−1 apyrase, a scavenger
of ADP, while platelet response to 50 nM U46619 plus 10 µM
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TABLE 5 | Effects of calcium chelators BAPTA-AM 20 µM (intracellular calcium chelator) or EGTA 1 mM (extracellular calcium chelator) on the expression of the active
fibrinogen receptor and P-Selectin (CD62) in washed platelets stimulated with U46619 1 µM or U46619 50 nM + epinephrine (epi) 10 µM.
Active fibrinogen receptor CD62+
Conditions With
apyrase
Without
apyrase
With
apyrase
Without
apyrase
Resting 0.83 ± 0.49
n = 8
1.10 ± 0.63
n = 10
2.03 ± 1.37
n = 6
3.46 ± 0.88
n = 4
+ BAPTA 20 µM 0.67 ± 0.37
n = 7
0.64 ± 0.22
n = 5
0.20 ± 0.21
n = 5∗
0.26 ± 0.23
n = 5∗
U46619 50 nM + Epi 10 µM 16.70 ± 20.27
n = 9∗
29.66 ± 23.41
n = 9∗
12.48 ± 6.21
n = 6∗
26.28 ± 13.47
n = 6∗
U46619 50 nM + Epi 10µM + BAPTA 20 µM 0.71 ± 0.35
n = 9†
3.49 ± 7.61
n = 8†
0.87 ± 0.92
n = 6†
0.71 ± 0.59
n = 7∗†
U46619 50 nM + Epi 10 µM + EGTA 1.02 ± 1.05
n = 6
1.80 ± 2.16
n = 6†
13.73 ± 9.74
n = 6
27.51 ± 15.25
n = 6
U46619 1 µM 1.38 ± 0.49
n = 8∗
20.85 ± 23.83
n = 6∗
3.80 ± 1.85
n = 6
18.54 ± 7.37
n = 6∗
U46619 1 µM + BAPTA 20 µM 0.63 ± 0.41
n = 8†
0.74 ± 0.28
n = 6
1.00 ± 0.96
n = 5†
0.78 ± 0.67
n = 6†
U46619 1 µM + EGTA 0.73 ± 0.55
n = 6†
0.86 ± 0.49
n = 6
4.16 ± 2.00
n = 6
23.41 ± 15.45
n = 6
Mean ± SD, ∗P < 0.05 stimulated vs. resting platelets, †P < 0.05 stimulated + BAPTA/EGTA vs. stimulated. In the presence of ASA 100 µM, eptifibatide 10 µg mL−1,
with and without apyrase 10 U mL−1. Data are expressed as % of positive events. One-way ANOVA, followed by Newman–Keuls as post hoc test was applied to compare
each agonist in the presence or absence of inhibitors with resting conditions. Active fibrinogen receptor and CD62 were separately analyzed.
FIGURE 5 | Platelet aggregation induced by U46619 1 µM and U46619 50 nM + epi 10 µM. Washed platelets in presence or absence of apyrase VII were
pre-treated with the NADPH oxidase inhibitor apocynin 300 µM, the reactive oxygen species (ROS) scavenger EUK-134 250 µM or the intracellular calcium chelator
BAPTA-AM 20 µM, respectively. Data are expressed as Mean ± SE.
epinephrine is not altered by apyrase (see Tables 2, 3) (Minuz
et al., 2006). Therefore, all the experiments exploring the TXA2
signaling pathways were performed in the presence of apyrase
10 U mL−1.
We confirm the role of Src in platelet secretion performing
our experiments in the absence of any signal ensuing from
released ADP and under non-aggregating conditions. In fact,
both dasatinib ex vivo (Table 2) and PP2 in vitro (Table 1) blunted
P-selectin expression also when activation of the fibrinogen
receptor was prevented by eptifibatide (Li et al., 2010b). Under
the same experimental conditions, tyrosine kinase signaling
also modulates the activation of αIIbβ3 and platelet aggregation
(Tables 2, 3), as previously observed (Minuz et al., 2006;
Li et al., 2010a). This finding is partly at variance with the
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TABLE 6 | Effect of the NADPH oxidase inhibitor apocynin 300 µM and the ROS
scavenger EUK-134 250 µM on the expression of P-Selectin (CD62P) and of
active form of fibrinogen receptor in washed platelets pre-treated with ASA
100 µM and apyrase VII 10 U mL−1.
Conditions CD62 Active
fibrinogen
receptor
Resting 2.08 ± 1.26
n = 12
0.72 ± 0.43
n = 12
+ Apocynin 300 µM 1.09 ± 0.10
n = 4
0.35 ± 0.13
n = 4
+ EUK-134 250 µM 0.87 ± 0.11
n = 4
0.30 ± 0.11
n = 4
U46619 1 µM 6.97 ± 2.88
n = 6∗∗∗
0.97 ± 0.56
n = 6
+ Apocynin 300 µM 3.18 ± 0.89
n = 5†
0.48 ± 0.17
n = 5
+ EUK-134 250 µM 1.71 ± 0.44
n = 4†
1.49 ± 0.17
n = 4
U46619 50 nM + epi 10 µM 16.47 ± 9.90
n = 10∗∗∗
9.14 ± 9.24
n = 10∗
+ Apocynin 300 µM 9.20 ± 4.84
n = 6‡
2.43 ± 2.00
n = 6∗
+ EUK-134 250 µM 6.06 ± 7.40
n = 11‡
3.63 ± 3.61
n = 11∗
Mean ± SD, ∗∗∗P < 0.0001 vs. resting, ∗P < 0.05 vs. resting, †P < 0.0001 vs.
U46619, 1 µM, ‡P < 0.05 vs. U46619 50 nM + epinephrine 10 µM. Data are
expressed as % of positive events. One-way ANOVA, followed by Newman–Keuls
as post hoc test was applied to compare each agonist in the presence or absence
of inhibitors with resting conditions. Active fibrinogen receptor and CD62 were
separately analyzed.
previous observation that dasatinib does not inhibit P-selectin
expression in thrombin or ADP-simulated platelets (Gratacap
et al., 2009).
Src phosphorylation is an early event in the pathways
operated by TXA2 analogs. To locate Scr activation, we
investigated calcium signals. We found that an increase in
intracellular calcium is necessarily required for functional
responses and Src phosphorylation. The maximum increase in
free intracellular calcium was observed with high concentrations
of U46619. Notably, while low U46619 has limited effects
on intracellular calcium, a sustained increase was observed
adding epinephrine to platelet preparations (Figure 2 and
Table 2). The effects of 1 µM U46619 are partly dependent
on extracellular calcium entry, as shown in the experiments
with EGTA (Figure 3) (Sage and Rink, 1987). The contribution
of calcium entry to the increase in free intracellular calcium
was evident when 50 nM U46619 plus 10 µM epinephrine
were tested. This finding is in agreement with previous
observations indicating that epinephrine increased both the
rate and amplitude of the rise in cytosolic free calcium in
response to sub-threshold concentrations of thrombin and
PAF, independently from the engagement of the fibrinogen
receptor and platelet aggregation (Powling and Hardisty,
1988).
Consistently with the observation that Src phosphorylation
is not required for thrombin-induced calcium entry (Harper
and Sage, 2006), calcium increase is not altered by PP2
(Table 4) in our model (Dorsam et al., 2005; Harper and Sage,
2006).
To define which G proteins were implicated in free
intracellular calcium increase downstream TP we compared
the effects of different doses of U46619 with those of 8
iso-PGF2α, capable of inducing platelet shape change, but
not platelet secretion and aggregation (Minuz et al., 1998).
Previous investigation consistently demonstrated that platelet
functional responses to 8-iso-PGF2α implicate G13-coupled
TPα receptor and P38 Mitogen Activated Protein Kinase
(MAPK) (Minuz et al., 2002; Zhang et al., 2006). This was
confirmed by the pharmacodynamic analysis of G-protein
activation by thromboxane analogs, showing that 8 iso-PGF2α
displays high affinity for TPα, but is unable to activate Gq
(EC50 210 µM) while activating G13 (EC50 34 µM). U46619
activates at similar concentrations both G13 and Gq (EC50
31 µM and 39 µM, respectively) (Zhang et al., 2009). However,
functional responses both to 8 iso-PGF2α and U46619 are
observed in the nanomolar range of concentrations, indicating
that platelet activation occurs also in the presence of a
receptor activation with limited downstream intracellular signals
(Minuz et al., 1998, 2002; Zhang et al., 2009). The dose-
dependency of calcium increase with U46619 is consistent
with differences in Gq activation downstream TPα. Recently
the role of focal adhesion kinase Pyk2 has been demonstrated
to link calcium signals and Src activation (Canobbio et al.,
2015), giving a plausible explanation also for the hierarchy
in the signaling events we observed in U46619-stimulated
platelets.
The addition of epinephrine, which does not per se increase
intracellular calcium, potentiates the effects of low doses
U46619. This is consistent with a model in which epinephrine
synergises with U46619 to promote a sustained calcium response,
through an altered channel activity by reducing the basal,
cAMP-dependent phosphorylation of InsP3 receptors, increasing
their responsiveness to agonists (Li et al., 2003; Hardy et al., 2004;
Xiang et al., 2010).
We can define a threshold concentration of free intracellular
calcium that is required to induce Src activation and a second
level that is required for the release reaction and the αIIbβ3
activation (Figure 7). This is demonstrated by the ability of PP2
or BAPTA to prevent all these functional events and by the
evidence that 8-iso-PGF1α does not synergize with epinephrine to
increase intracellular calcium (Table 4). When high doses (1 µM)
of U46619 are tested, most of the functional responses, except
for granule secretion, in washed platelets are dependent on ADP
released from dense granules (Minuz et al., 2006). Nevertheless,
Src pathway is not inhibited, being crucially implicated in
the residual secretion of the α granules and activation of the
fibrinogen receptor that is observed in the presence of apyrase
(Gratacap et al., 2009). This is also consistent with the observation
that restoring ADP reverses the inhibitory effects of PP2 in
thrombin and TXA2 stimulated platelets (Li et al., 2010b).
Calcium-dependent ROS generation represents a crucial step
in platelet activation as a signal to elicit functional responses to
U46619 in platelet. These are equally blunted by a scavenger of
ROS and by the NOX inhibitor apocynin, thus demonstrating
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FIGURE 6 | Reactive oxygen species generation (measured as Fluorescence Arbitrary Units-FUA) induced by agonists in washed platelets in presence of apyrase VII
10 U mL−1, ASA 100 µM and eptifibatide 10 µg mL−1 (A,B). Platelets were pre-treated with the NADPH oxidase inhibitor apocynin 300 µM, the intracellular
calcium chelator BAPTA-AM 20 µM (A), or the tyrosine kinase inhibitor dasatinib 150 nM (B). Repeated-measures One-way ANOVA, with the Newman–Keuls test
for post hoc analysis were applied to compare independently each platelet agonist in the presence or absence of inhibitors with resting conditions. Data are
expressed as Mean ± SE. Indicates the signficance level: ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.0001.
that these enzymes are responsible for ROS generation. Calcium
is implicated in the release of ROS, since generation is reduced
following store depletion (Rosado et al., 2001).
Seven NOX family members are so far been discovered in
mammalian cells. Only two isoforms have been identified in
platelets: NOX2 is the main catalytic unit present in platelets, but
recently a role for the isoform NOX1 has been reported (Walsh
et al., 2014). Platelet agonists like thrombin (Wachowicz et al.,
2002), collagen (Pignatelli et al., 1998), and thromboxane analog
U46619 (Begonja et al., 2005) induce ROS generation. ROS act
as signaling mediators in platelets activation (Krötz et al., 2002).
Our results indicate that NOX contributes to ROS production
in stimulated platelet and is implicated in the activation of
αIIbβ3 integrin and the release reaction, independently of
aggregation and integrin-dependent amplificatory signals. The
NOX inhibitor has no effects on ROS generation in resting
platelets, while calcium signals are required both for basal
and stimulated ROS generation. However, only NOX5 has
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FIGURE 7 | Graphs summarize the relationships between TP receptor activation, signaling pathways and functional responses in platelets stimulated with different
amounts of the TXA2 analog U46619 and the cooperative effects of epinephrine. +, ++, +++ Represent differences in the implication of the signaling pathways.
so far been shown to be calcium-dependent (Pandey et al.,
2011). It has been demonstrated that the synthesis of ROS by
oxLDL/CD36 in platelets requires Src-family kinases and protein
kinase C (PKC)-dependent phosphorylation and activation of
NOX2 (Magwenzi et al., 2015). More recently, it has been
demonstrated that the NOX1 and the NOX2 knock-out mice
exhibit distinct platelet response to agonists. In fact NOX1 -/y
show specifically hyporesponsiveness to U46619 and thrombin,
both acting through G protein-coupled receptors, resulting in
blunted platelet aggregation and reduced ADP release (Delaney
et al., 2016). Cumulating our observations with those obtained
in the murine model, NOX1-derived ROS in platelet activation
can be located downstream TP receptor, with amplificatory
effects on calcium and tyrosine-kinase signaling response. Since
apocynin does not inhibit ROS generation in resting platelets,
we speculate that mitochondria are mostly involved in ROS
generation in the absence of platelet stimulation. We also
observed a distinct role of tyrosine kinases in collagen-dependent
ROS generation, as demonstrated using dasatinib in vitro,
confirming the contribution of signals downstream GPVI-ITAM
in the activation of NAPDH oxidase activation (Qiao et al., 2018).
This was not observed in G-protein coupled TP and adrenergic
receptor depended ROS generation. A limitation in our study is
the lack of in depth mechanistic investigation.
We conclude that TXA2 analogs that cause a partial
occupation of the TP receptor and activation of a G13-dependent
pathway, such as 8-iso-PGF2α, have limited effects on platelets
inducing shape change and increased adhesion (Smyth, 1996;
Minuz et al., 1998). When a Gq-dependent calcium signal
is induced (even if limited, also in cooperation with a
Gz-dependent pathway), platelet secretion and aggregation are
induced, also through further activation of the Src kinase
pathway. High doses of TXA2 activate a Gq pathway inducing
platelet activation independently of the Rho kinase pathway,
but this does not make redundant the signals ensuing from
phosphorylated Src. In our opinion, the proposed model
of platelet activation induced by TXA2 analogs effectively
explains all the functional events deriving from TP occupancy.
Our study mostly addresses the functional role of the main
signaling pathways downstream TP using specific inhibitors to
identify changes in platelet responses. The cooperative effects
of epinephrine on platelet activation by low amounts of a
Thromboxane analog suggests mostly explanations for biological
phenomena that could be of clinical relevance rather than specific
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targets of pharmacological intervention. Further mechanistic and
pharmacological investigation is advisable.
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